Adverse Drug Interactions with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 1 February 1993
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 8 (2) , 99-127
- https://doi.org/10.2165/00002018-199308020-00002
Abstract
The prevalence and incidence of adverse drug interactions involving nonsteroidal anti-inflammatory drugs (NSAIDs) remains unknown. To identify those proposed drug interactions of greatest clinical significance, it is appropriate to focus on interactions between commonly used and/ or commonly coprescribed drugs, interactions for which there are numerous well documented case reports in reputable journals, interactions validated by well designed in vivo human studies and those affecting high-risk drugs and/or high-risk patients. While most interactions between NSAIDs and other drugs are pharmacokinetic, NSAID-related pharmacodynamic interactions may be considerably more important in the clinical context, and prescriber ignorance is likely to be a major determinant of many adverse drug interactions. Prescribing NSAIDs is relatively contraindicated for patients on oral anticoagulants due to the risk of haemorrhage, and for patients taking high-dose methotrexate due to the dangers of bone marrow toxicity, renal failure and hepatic dysfunction. Combination NSAID therapy cannot be justified as toxicity may be increased without any improvement in efficacy. Where lithium or anti-hypertensives are coprescribed with NSAIDs, close monitoring is mandatory for lithium toxicity and hypertension, respectively, and aspirin (acetylsalicylic acid) or sulindac are preferred. Phenytoin or oral hypoglycaemic agents may be administered with NSAIDs other than pyrazoles and salicylates provided that patients are monitored carefully at the initiation and cessation of NSAID treatment. Digoxin, aminoglycosides and probenecid may be coprescribed with NSAIDs, but close monitoring is required, particularly for high-risk patients such as the elderly. Indomethacin and triamterene should be avoided due to the risk of renal failure. High dose aspirin should be replaced by naproxen in patients on valproic acid (sodium Valproate) and care is required when corticosteroids are administered to patients taking salicylates long term in high dosage. Interactions between NSAIDs and antacids or cholestyramine are generally avoidable. Adverse drug interactions involving NSAIDs may be limited by rational prescribing and by careful monitoring, particularly for high-risk patients, drugs and therapy periods.Keywords
This publication has 98 references indexed in Scilit:
- Pharmacokinetic Drug Interactions with Nonsteroidal Anti-Inflammatory DrugsClinical Pharmacokinetics, 1990
- Effects of Antacids on the Clinical Pharmacokinetics of DrugsClinical Pharmacokinetics, 1990
- Health Implications of Drug InteractionsDrug Safety, 1990
- Drug Interactions Involving Aspirin (Acetylsalicylic Acid) and Salicylic AcidClinical Pharmacokinetics, 1989
- Protein Binding Drug Displacement InteractionsClinical Pharmacokinetics, 1989
- Variability in Response to NSAIDsDrugs, 1988
- Clinical Pharmacology of NSAIDsThe Journal of Clinical Pharmacology, 1988
- Protein Binding as a Primary Determinant of the Clinical Pharmacokinetic Properties of Non-Steroidal Anti-Inflammatory DrugsClinical Pharmacokinetics, 1987
- Interaction Between Sulindac and Warfarin: Different Results in Normal Subjects and in an Unusual Patient with a Potassium‐Losing Renal Tubular DefectThe Journal of Clinical Pharmacology, 1979
- Drug Use in the ElderlyDrugs, 1978